

### AMENDMENTS TO THE CLAIMS

1-13. (Cancelled)

14. (Currently amended) A drug for an antibody therapy of cancer, which comprises a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme and, an antibody drug and a complement as active ingredients.

15. (Original) The drug according to claim 14, wherein the hydrolytic enzyme is pepsin.

16. (Previously presented) The drug according to claim 14, wherein degradation rate of the lactoferrin hydrolysate is 6 to 20%.

17. (Previously presented) The drug according to claim 14, wherein the lactoferrin hydrolysate has a number average molecular weight of 500 to 5000.

18. (Previously presented) The drug according to claim 14, wherein the antibody drug is an anti-CD20 antibody, anti-HER2 monoclonal antibody or anti-17-1A (human tumor-related epithelial cell adhesion factor) antibody.

19. (Previously presented) The drug according to claim 14, wherein the cancer is a cancer having resistance to the antibody drug.

20. (Currently amended) A drug for an antibody therapy of cancer, which comprises ~~any one type or a mixture of two or more types of~~ the following peptides of (a) ~~to (d)~~ and/or (c), an antibody drug and a complement as active ingredients:

(a) a peptide ~~having the~~ comprising an amino acid sequence consisting of the amino acid sequence shown as SEQ ID NO: 2;

(b) a peptide ~~having the amino acid sequence of the amino acid numbers 36 to 60 in the amino acid sequence of SEQ ID NO: 1, which includes substitution, deletion, addition or inversion of one or more amino acid residues thereof, and having an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer;~~

(c) a peptide ~~having the~~ comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 3;

(d) a peptide ~~having the amino acid sequence of the amino acid numbers 36 to 61 in the amino acid sequence of SEQ ID NO: 1, which includes substitution, deletion, addition or inversion of~~

~~one or more amino acid residues thereof, and having an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer.~~

21. (Original) The drug according to claim 20, wherein the antibody drug is an anti-CD20 antibody, anti-HER2 monoclonal antibody or anti-17-1A (human tumor-related epithelial cell adhesion factor) antibody.

22. (Previously presented) The drug according to claim 20, wherein the cancer is a cancer having resistance to the antibody drug.

23. (Currently amended) A method of treating cancer comprising administering an antibody drug and a complement and administering a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme in an amount sufficient to enhance a complement-dependent cytotoxic activity of ~~an-the~~ antibody drug and/or the complement in an antibody therapy of cancer to a subject in need thereof, wherein administration of the lactoferrin hydrolysate is before or after administration of the antibody drug and/or complement or simultaneously with the antibody drug and/or complement.

24. (Cancelled)

25. (Currently amended) A method for enhancing a complement-dependent cytotoxic activity of an antibody drug and/or a complement in an antibody therapy of cancer using the antibody drug and the complement, which comprises administering an antibody drug and a complement and administering to a patient a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme to a patient in need thereof and which has an action of enhancing the complement-dependent cytotoxic activity of the antibody drug and/or the complement in an antibody therapy of cancer, wherein the lactoferrin hydrolysate is administered before or after administration of the antibody drug and/or complement or simultaneously with the antibody drug and/or complement.

26. (Currently amended) A method for enhancing a complement-dependent cytotoxic activity of an antibody drug and/or a complement in an antibody therapy of cancer using the antibody drug and the complement, which comprises administering ~~any one type or a mixture of two or more types of an~~ antibody drug and a complement and administering the following

peptides of (a) ~~to (d)~~ and/or (c) to a patient in need thereof wherein administration of the peptide(s) is before or after administration of the antibody drug and/or complement or simultaneously with the antibody drug and/or complement:

(a) a peptide having ~~the~~ comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 2;

(b) a peptide having the amino acid sequence of the amino acid numbers 36 to 60 in the amino acid sequence of SEQ ID NO: 1, which includes substitution, deletion, addition or inversion of one or more amino acid residues thereof, and having an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer;

(c) a peptide having ~~the~~ comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 3;

(d) a peptide having the amino acid sequence of the amino acid numbers 36 to 61 in the amino acid sequence of SEQ ID NO: 1, which includes substitution, deletion, addition or inversion of one or more amino acid residues thereof, and having an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer.